Evaluating Agios Pharmaceuticals After 16% Rally and Positive Early Data on Mitapivat in Sickle Cell Disease [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
The stock has caught the eye of investors recently, and for good reason. Over the last month, Agios has rallied 16.2%, adding to a stellar year-to-date return of nearly 33%. Even with that strong surge, the 1-year performance remains in the red at -7.0%. However, if you zoom out to a three-year window, the stock is up an impressive 56.8%. These mixed numbers reflect a company in transition, and a market that has grown more optimistic, especially as the broader biotech industry responds to shifting regulatory expectations and growing interest in rare disease therapeutics. Agios currently posts a robust value score of 5 out of 6, meaning it passes almost every major undervaluation check. That's not something you see every day in this sector, where high-growth potential often comes with a premium price tag. So, is now a rare opportunity to own Agios before the market fully catches on? Let's break down how Agios stacks up under different valuation approaches, and reveal a smarter way
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.MarketBeat
- Agios Pharmaceuticals (NASDAQ:AGIO) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.MarketBeat
- Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals (NASDAQ:AGIO) was given a new $32.00 price target on by analysts at Truist Financial Corporation.MarketBeat
AGIO
Earnings
- 10/30/25 - Beat
AGIO
Sec Filings
- 12/5/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form 4
- AGIO's page on the SEC website